TY - CHAP
T1 - The safety and efficiency of addressing ards using stem cell therapies in clinical trials
AU - Rezoagli, Emanuele
AU - Murphy, Emma J.
AU - Laffey, John
AU - O’toole, Daniel
N1 - Publisher Copyright:
© SprSpringer Nature Switzerland AG 2019. All rights reserved.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Acute Respiratory Distress Syndrome (ARDS) is a complex and debilitating disease of the lungs, which continues to have a high mortality rate and huge disease burden on patients. Incidence is rising, possibly due to greater awareness leading to more diagnoses rather than a change in the underlying rate. It arises from multiple etiologies, though pathogenic infection, termed pneumonia, is the most prevalent and widely studied. The distinct pathophysiology and rapid evolution of ARDS makes it uniquely challenging with regard to therapeutics development and, to date, no medicines are licensed for specific therapy. Antibiotics, ventilation, and other organ support remain intervention standards.
AB - Acute Respiratory Distress Syndrome (ARDS) is a complex and debilitating disease of the lungs, which continues to have a high mortality rate and huge disease burden on patients. Incidence is rising, possibly due to greater awareness leading to more diagnoses rather than a change in the underlying rate. It arises from multiple etiologies, though pathogenic infection, termed pneumonia, is the most prevalent and widely studied. The distinct pathophysiology and rapid evolution of ARDS makes it uniquely challenging with regard to therapeutics development and, to date, no medicines are licensed for specific therapy. Antibiotics, ventilation, and other organ support remain intervention standards.
UR - http://www.scopus.com/inward/record.url?scp=85085830551&partnerID=8YFLogxK
U2 - 10.1007/978-3-030-29403-8_12
DO - 10.1007/978-3-030-29403-8_12
M3 - Chapter
AN - SCOPUS:85085830551
SN - 9783030294021
SP - 219
EP - 238
BT - Stem Cell-Based Therapy for Lung Disease
PB - Springer International Publishing
ER -
